# PT-141 Half-Life and Pharmacokinetics in the Research Record > PT-141 half-life is about 2.7 hours after subcutaneous dosing per the prescribing information. The PT-141 pharmacokinetic record: Tmax, distribution, clearance, excretion, and the discontinued intranasal route. About 2.7 hours, subcutaneous — with a fast peak, a small volume of distribution, and a measured effect that can outlast plasma levels. The PK record, read as a single quantity against its sources. ## In plain English Half-life is how long it takes the body to clear half of a drug from the blood. For **PT-141 half-life**, that figure is about 2.7 hours after a subcutaneous injection (injected just under the skin), per the approved drug's label [13]. The peak blood level arrives fast — within roughly half an hour to an hour — and the bulk is gone within about a day [13]. One useful wrinkle: in a brain-imaging study the effect on desire was still measurable up to 24 hours, so what a person experiences can outlast what is in the bloodstream [5]. The numbers below are study and label findings, not a schedule to follow. ## The Half-Life of PT-141 The US prescribing information reports a terminal half-life of approximately **2.7 hours** (range 1.9–4.0 h) after subcutaneous administration [13]. Early intranasal studies in men reported a shorter terminal half-life of 1.85–2.09 hours [6]. The cyclic lactam structure of the peptide confers greater stability than linear melanocortin peptides, which is part of why a small peptide drug is viable as an as-needed injection at all [13]. The rest of the pharmacokinetic profile is compact. Volume of distribution is about 25.0 L and clearance about 6.5 L/hr, with roughly 21% serum protein binding [13]. Metabolism proceeds by hydrolysis of the cyclic-peptide amide bonds and peptidase digestion [13]. The NIH LiverTox monograph notes that bremelanotide is cleared with minimal drug–drug interactions and is associated with only mild serum-enzyme elevations and rare instances of clinically apparent liver injury [12]. ## How Long Does PT-141 Last? **How long does PT-141 last** has two answers, because pharmacokinetics and pharmacodynamics diverge here. By the blood, not long: with a terminal half-life near 2.7 hours, most of a subcutaneous dose is cleared within roughly a day [13]. By the experienced effect, longer: the mechanistic fMRI study measured increased sexual desire for up to 24 hours after MC4R agonism, well beyond the plasma window [5]. That gap is why [how long PT-141 lasts](/half-life#duration) is best described as a measured effect that can outlast circulating drug, not as a fixed duration. The label's instruction to dose at least 45 minutes before anticipated activity reflects onset, not offset [13]. ## Onset of Action in the Studies Subcutaneous bremelanotide reaches median peak concentrations within about 0.5–1.0 hour, and the label directs dosing at least 45 minutes before anticipated activity [13]. In the early intranasal erectile-dysfunction research, the first erection was reported at roughly 30 minutes after dosing [6]. Onset is therefore measured in tens of minutes, consistent with a fast-absorbed subcutaneous peptide [13]. None of this is a dosing instruction — it is the timing the trials and the label document. ## How Long PT-141 Stays in the System With a terminal half-life near 2.7 hours, the bulk of a subcutaneous dose is cleared within roughly a day [13]. Elimination is split between routes: a radiolabeled study found excretion was about 64.8% renal and 22.8% fecal [13]. Metabolism is by hydrolysis of the cyclic-peptide bonds and peptidase digestion rather than by the cytochrome P450 enzymes that drive many small-molecule interactions, consistent with the minimal drug–drug-interaction profile noted in the LiverTox monograph [12]. ## The Intranasal Formulation and Why It Was Dropped Before the subcutaneous formulation, PT-141 was developed as a nasal spray. Early intranasal PT-141 produced a dose-dependent erectile response above 7 mg in men, with median Tmax of 0.50 h and terminal half-life 1.85–2.09 h [6]. The intranasal program was discontinued because of pharmacokinetic variability, and development moved to the subcutaneous route that was ultimately approved [6]. So **does PT-141 nasal spray work** has a historical answer — it produced a measurable response in early trials — and a regulatory one: the approved product is a subcutaneous injection, not a nasal spray, and the intranasal route is not approved [13]. ## Field reports (not clinical data) The following describes commonly-reported, first-hand impressions from research and community discussion. **These are unverified user reports, not peer-reviewed evidence, not attributable to any study, and not advice.** They are included only to record what people describe, and no figure here is a clinical measurement. Researchers handling material labeled "PT-141" frequently describe a fast onset — a sense of effect within roughly half an hour to an hour — broadly echoing the documented Tmax, though impressions of duration vary widely and are not a measured half-life [13]. A recurring community note is that the felt effect can persist into the following day, which people sometimes contrast with the short plasma half-life. None of this should be read as a dose, a schedule, or an endorsement; the cited pharmacokinetic figures above are the evidence, and these impressions are not. --- A clinician's measured read of the bremelanotide record — the confirmed trial findings raised plainly, the tolerability and contraindication facts pressed in first, and the unverified field reports kept off to one side; no clinic behind the surface and nothing here dosed, dispensed, or sold.